Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
- PMID: 29544767
- DOI: 10.1016/j.cmi.2018.01.002
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
Abstract
The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct microscopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acute myelogenous leukaemia or myelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging.
Keywords: Aspergillosis; Diagnosis; Haematology; Invasive fungal infection; Transplantation; Treatment.
Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Invasive mould infections in the ICU setting: complexities and solutions.J Antimicrob Chemother. 2017 Mar 1;72(suppl_1):i39-i47. doi: 10.1093/jac/dkx032. J Antimicrob Chemother. 2017. PMID: 28355466 Review.
-
[Expert consensus on the diagnosis and treatment of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease].Zhonghua Jie He He Hu Xi Za Zhi. 2024 Jul 12;47(7):604-622. doi: 10.3760/cma.j.cn112147-20231228-00399. Zhonghua Jie He He Hu Xi Za Zhi. 2024. PMID: 38955746 Chinese.
-
ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children.Clin Microbiol Infect. 2019 Sep;25(9):1096-1113. doi: 10.1016/j.cmi.2019.05.019. Epub 2019 May 31. Clin Microbiol Infect. 2019. PMID: 31158517
-
Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: A modelling study of different strategies.Int J Antimicrob Agents. 2019 Mar;53(3):284-293. doi: 10.1016/j.ijantimicag.2018.10.021. Epub 2018 Nov 2. Int J Antimicrob Agents. 2019. PMID: 30395989
-
Invasive Pulmonary Aspergillosis.Semin Respir Crit Care Med. 2020 Feb;41(1):80-98. doi: 10.1055/s-0039-3401990. Epub 2020 Jan 30. Semin Respir Crit Care Med. 2020. PMID: 32000286 Review.
Cited by
-
CAF to the Rescue! Potential and Challenges of Combination Antifungal Therapy for Reducing Morbidity and Mortality in Hospitalized Patients With Serious Fungal Infections.Open Forum Infect Dis. 2024 Oct 30;11(11):ofae646. doi: 10.1093/ofid/ofae646. eCollection 2024 Nov. Open Forum Infect Dis. 2024. PMID: 39544494 Free PMC article. Review.
-
The epidemiological characteristics of invasive pulmonary aspergillosis and risk factors for treatment failure: a retrospective study.BMC Pulm Med. 2024 Nov 8;24(1):559. doi: 10.1186/s12890-024-03381-3. BMC Pulm Med. 2024. PMID: 39511508 Free PMC article.
-
Review of the novel antifungal drug olorofim (F901318).BMC Infect Dis. 2024 Nov 7;24(1):1256. doi: 10.1186/s12879-024-10143-3. BMC Infect Dis. 2024. PMID: 39511507 Free PMC article. Review.
-
Seroprevalence and prognostic value of Aspergillus-specific IgG among non-neutropenic invasive pulmonary aspergillosis patients: a prospective multicenter study.Pneumonia (Nathan). 2024 Nov 5;16(1):28. doi: 10.1186/s41479-024-00154-8. Pneumonia (Nathan). 2024. PMID: 39497226 Free PMC article.
-
ProcCluster® and procaine hydrochloride inhibit the growth of Aspergillus species and exert antimicrobial properties during coinfection with influenza A viruses and A. fumigatus in vitro.Front Cell Infect Microbiol. 2024 Oct 15;14:1445428. doi: 10.3389/fcimb.2024.1445428. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39473925 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
